Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673M, up 20.2% year over year. Operating margin was -79.5% and net margin -85.4%, on a free-cash-flow margin of -70.1% with capital expenditure at 0.9% of revenue. Every figure is computed directly from RARE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $673M | -79.5% | -85.4% |
| FY2024 | $560M | -95.7% | -101.6% |
| FY2023 | $434M | -131.1% | -139.9% |
| FY2022 | $363M | -178.6% | -194.7% |
| FY2021 | $351M | -108.6% | -129.2% |
How does RARE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.